Home > Journals > Minerva Pediatrics > Past Issues > Articles online first > Minerva Pediatrics 2021 Jul 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Pediatrics 2021 Jul 21

DOI: 10.23736/S2724-5276.21.06529-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Prevention of type 1 diabetes: where we are and where we are going

Giulio FRONTINO 1, Salvatore GUERCIO NUZIO 2, Andrea E. SCARAMUZZA 3, Giuseppe D'ANNUNZIO 4, Sonia TONI 5, Felice CITRINITI 6, Riccardo BONFANTI 1, 7

1 Diabetes Research Institute, Department of Pediatrics, IRCCS San Raffaele Scientific Institute, Milano, Italy; 2 Division of Pediatric, Santa Maria della Speranza Hospital, Battipaglia, ASL Salerno, Salerno, Italy; 3 Division of Pediatrics, ASST Cremona, Maggiore Hospital, Cremona, Italy; 4 Pediatric Clinic and Endocrinology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy; 5 Diabetology and Endocrinology Unit, Meyer Children Hospital, Firenze, Italy; 6 Department of Pediatrics, Pugliese-Ciaccio Hospital, Catanzaro, Italy; 7 Università Vita-Salute San Raffaele, Milan, Italy


PDF


T1D (T1D) is one of the most frequent chronic disease in children and is associated to the risk of severe acute and chronic complications. There are about 550000 children with T1D in the world and about 86000 children are diagnosed with T1D every year and its incidence is ever increasing. In this narrative review we will discuss current and future perspectives in T1D prevention strategies as well as their pitfalls. It is important to remember that for the first time one drug, in particular Teplizumab (antibody anti CD3) is going to be accepted for treatment in stage 2 of type 1 diabetes mellitus: this represent the onset of a new era.


KEY WORDS: Type 1 diabetes; Prevention; Immune intervention; B cell preservation

top of page